ORCL Investors Have Opportunity to Join Oracle Corporation Fraud Investigation with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–$ORCL—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims... Read more.
FPT Recognized in Everest Group Banking IT Services PEAK Matrix® Assessment 2025
HANOI, Vietnam–(BUSINESS WIRE)–#FPT–Global IT services provider FPT has been positioned as a Major Contender in the Everest Group Banking IT Services... Read more.
H2O.ai Accredited by IMDA Singapore for Enterprise Generative AI Solutions
SINGAPORE–(BUSINESS WIRE)–H2O.ai, a pioneer in sovereign AI and the world’s leading agentic and predictive AI company, today announced its latest renewal... Read more.
KBRA Assigns Preliminary Ratings to PEAC Solutions Receivables 2026-1 LLC
NEW YORK–(BUSINESS WIRE)–#creditratingagency–KBRA assigns preliminary ratings to five classes of notes issued by PEAC Solutions Receivables 2026-1... Read more.
KKR Completes US$2.5 Billion Asia Private Credit Fundraise
HONG KONG–(BUSINESS WIRE)–KKR, a leading global investment firm, today announced the completion of a US$2.5 billion fundraise focused on committing capital... Read more.
VENU Investigation: Investors Encouraged to Contact Kirby McInerney LLP
NEW YORK–(BUSINESS WIRE)–The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Venu Holding Corporation (“Venu”... Read more.
Woodside Executes JERA Winter Contract
PERTH, Australia–(BUSINESS WIRE)–Woodside Energy Trading Singapore Pte Ltd (Woodside) is pleased to announce the execution of a Sale and Purchase Agreement... Read more.
LAKE Investigation: Investors Encouraged to Contact Kirby McInerney LLP
NEW YORK–(BUSINESS WIRE)–The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Lakeland Industries, Inc. (“Lakeland”... Read more.
Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference
Samsung Bioepis plans to secure 20 biosimilars in its products and pipeline by 2030 The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab... Read more.
BigBear.ai Announces Full Conversion of 6.00% Convertible Senior Secured Notes Due 2029, Significantly Strengthening Balance Sheet
MCLEAN, Va.–(BUSINESS WIRE)–BigBear.ai (NYSE: BBAI) (the “Company”), a leading provider of mission-ready artificial intelligence solutions for national... Read more.